Treatment for CML has advanced significantly with the development of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib. These drugs target the BCR-ABL protein and have dramatically improved outcomes for patients. In some cases, a bone marrow transplant may be considered.
